A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
about
Pazopanib in the management of advanced soft tissue sarcomasBeyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinomaPazopanib in the treatment of advanced renal cell carcinomaChinese guidelines on the management of renal cell carcinoma (2015 edition)Sequence of treatment in locally advanced and metastatic renal cell carcinomaCurrent management and future directions in the treatment of advanced renal cell carcinoma-a latin american perspective: 10 years in reviewMultidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvementRisk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase InhibitorsProfile of pazopanib and its potential in the treatment of epithelial ovarian cancerIndividualising treatment choices in a crowded treatment algorithmClinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancerEvaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinomaHypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell CarcinomaInfluence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer PatientsImmunotherapy for metastatic renal cell carcinoma.Renal cell cancer: overview of the current therapeutic landscape.Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review.Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I studyMammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma.Metastasis-Initiating Cells in Renal Cancer.Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma.Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experiencePneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case seriesOverall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinomaRisks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysisDNA methylation biomarkers predict progression-free and overall survival of metastatic renal cell cancer (mRCC) treated with antiangiogenic therapies.IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib.BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ASunitinib re-challenge in advanced renal-cell carcinoma.Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry.Pazopanib as a second-line treatment for non-cytokine-treated metastatic renal cell carcinoma: a meta-analysis of the effect of treatment.A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapySorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors.Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinomaTreatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry.
P2860
Q26746205-A55637F4-12F9-481D-AAEF-95B94F6EAB05Q26766240-F78FC93C-0FC8-429C-ACA4-88624B91ABACQ26770413-FE0ACB47-9EC2-41BE-B857-51145B942386Q26772206-2C559D93-E50B-4968-8707-20F40EBF5153Q26773653-1609970A-B1B6-461A-A452-D2930E9F05C5Q26774515-09A94E11-9313-42F4-9600-B77994883155Q26801279-DBE6B96A-A44F-4944-A5A7-8E988722BB24Q26851417-EEE934B9-ED4D-448F-B746-D46739E9683FQ27011840-A093C049-7345-401D-B89F-8AACB24F3CE0Q27023669-7D94AF99-614A-4513-955E-BCD6FE89547AQ27024235-20C256B3-D2DA-48AA-B2BF-FFB5BB245885Q27028048-BB6DA6DF-072F-40E7-B1D9-D48995147EC4Q28066747-220B4F09-4C6C-4009-A746-D708F9147576Q28080163-6C356B86-E776-49FA-85A7-91F7C7FD7951Q30234458-2FD46854-E25F-4D28-BEF9-A5DE0DEF7FBBQ30248354-4F0D5546-0410-41C1-A6A1-C9932BF15301Q31010355-F9C6FECA-DDF9-4720-9606-6BE0C6A12262Q33419957-0D062348-E560-48D6-B8B3-116E5DE627E1Q33633424-D78B9D50-9B08-4381-A619-F2935F8B7AB3Q33712944-ADC1FD9B-8A8F-49CE-9A8D-357440DEBB77Q33770680-E7148140-1E0C-4B78-B30E-C316AA7B6DFEQ33885479-207333EE-5405-4D96-9344-4FD65AD1D926Q34077263-1C5ED548-EF16-4A46-A041-6F74880E70BEQ34077268-5828DF03-12A7-4120-8895-3E08314B22CEQ34105997-962C0D90-2D36-4782-BE66-5253456247FAQ34161033-5A3B0275-9646-4E69-AE49-4AA77DF18232Q34314062-4B061715-107C-439E-80BB-E4D6238A2656Q35052037-0EAC0516-C6B4-49F3-98B0-9C53585A09C1Q35118673-DCEBA856-8876-493D-AAF1-123A263BB5BEQ35122019-32434466-D871-495B-B8EE-F41641CDDC27Q35274936-09A4C8B8-F194-4F2B-8C39-DAE0F2E4CB32Q35534962-A484C7EF-B612-43EF-8A46-350EB37D3FF9Q35664516-3E81D7EA-0F7E-4EF8-B732-10569B87C91FQ35678358-F457E31A-5097-41B4-A5A6-52C035EE627BQ36048725-3856D42E-6063-4825-8983-87E1F11B0202Q36067852-188DFD21-0B28-4A5D-8051-E9CFC8B95C27Q36092829-37C28954-EDE4-4982-B119-5600698C62C9Q36241010-40E88D2C-73D2-44DA-8601-A216547DB5EDQ36287092-B4FE3565-8E56-453A-B66C-66C1E98A0BA6Q36384503-AF53C1D4-A58E-45B0-AFB8-9587AF9410F4
P2860
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A randomised, double-blind pha ...... val results and safety update.
@ast
A randomised, double-blind pha ...... val results and safety update.
@en
A randomised, double-blind pha ...... val results and safety update.
@nl
type
label
A randomised, double-blind pha ...... val results and safety update.
@ast
A randomised, double-blind pha ...... val results and safety update.
@en
A randomised, double-blind pha ...... val results and safety update.
@nl
prefLabel
A randomised, double-blind pha ...... val results and safety update.
@ast
A randomised, double-blind pha ...... val results and safety update.
@en
A randomised, double-blind pha ...... val results and safety update.
@nl
P2093
P1476
A randomised, double-blind pha ...... ival results and safety update
@en
P2093
Carlos H Barrios
Cezary Szczylik
Cora N Sternberg
Eunsik Lee
Ian D Davis
Jozef Mardiak
Juan J Zarba
Lauren McCann
Oleg A Gladkov
P304
P356
10.1016/J.EJCA.2012.12.010
P577
2013-01-12T00:00:00Z